Hot products 
-
Mouse Anti-CD2AP Recombinant Antibody (BR083) (CBMAB-BR083LY)
-
Mouse Anti-BZLF1 Recombinant Antibody (BZ.1) (CBMAB-AP705LY)
-
Mouse Anti-ARID1B Recombinant Antibody (KMN1) (CBMAB-A3546-YC)
-
Mouse Anti-GFAP Recombinant Antibody (5) (CBMAB-G0346-LY)
-
Mouse Anti-ACO2 Recombinant Antibody (V2-179329) (CBMAB-A0627-YC)
-
Mouse Anti-CCL18 Recombinant Antibody (64507) (CBMAB-C7910-LY)
-
Mouse Anti-BIRC5 Recombinant Antibody (6E4) (CBMAB-CP2646-LY)
-
Rat Anti-AChR Recombinant Antibody (V2-12500) (CBMAB-0990-CN)
-
Rabbit Anti-BAD (Phospho-Ser136) Recombinant Antibody (CAP219) (CBMAB-AP536LY)
-
Mouse Anti-APP Recombinant Antibody (5C2A1) (CBMAB-A3314-YC)
-
Mouse Anti-ARHGDIA Recombinant Antibody (CBCNA-009) (CBMAB-R0415-CN)
-
Mouse Anti-AAV-5 Recombinant Antibody (V2-503416) (CBMAB-V208-1402-FY)
-
Mouse Anti-BCL2L1 Recombinant Antibody (H5) (CBMAB-1025CQ)
-
Mouse Anti-COL12A1 Recombinant Antibody (CBYY-C3117) (CBMAB-C4560-YY)
-
Mouse Anti-ARID3A Antibody (A4) (CBMAB-0128-YC)
-
Rabbit Anti-CCN1 Recombinant Antibody (CBWJC-3580) (CBMAB-C4816WJ)
-
Mouse Anti-CASQ1 Recombinant Antibody (CBFYC-0863) (CBMAB-C0918-FY)
-
Mouse Anti-DLG1 Monolconal Antibody (4F3) (CBMAB-0225-CN)
-
Rabbit Anti-ABL1 (Phosphorylated Y185) Recombinant Antibody (V2-443434) (PTM-CBMAB-0001YC)
-
Mouse Anti-DMPK Recombinant Antibody (CBYCD-324) (CBMAB-D1200-YC)
Endometrial Cancer
Fig.1 Endometrial cancer
Endometrial cancer is a cancer originating from the endometrium, which is the lining of the womb and uterus. The first sign is most abnormal vaginal bleeding but not associated with menstrual periods. Other symptoms include pain with urination, pelvic pain or sexual intercourse. Endometrial cancer occurs overwhelmingly after menopause. About 40% of cases are related to obesity. Besides it is also associated with diabetes, excessive estrogen exposure and high blood pressure. Hereditary causes contribution to 2–10% of the endometrial cancer cases. The most common type of endometrial cancer is endometrioid carcinoma, which making up more than 80% of cases. The five-year survival rate for endometrial adenocarcinoma following appropriate treatment is around 80%. Prognostic markers, like Serum HE4 have been studied recently.
Loading...



